Recent policies to enhance Renin-angiotensin prescribing efficiency in Europe; implications for the future

L. Voncina, B. B. Godman, V. Vlahovic-Palcevski, M. Bennie, I. Bishop

Research output: Contribution to journalConference Contribution

6 Citations (Scopus)

Abstract

Renin - angiotensin (RA) drugs (Angiotensin Converting Enzyme Inhibitors - ACEIs - and Angiotensin Receptor Blockers - ARBs) are accepted treatments for hypertension and Congestive Heart Failure. Coughing can occur with ACEIs leading to development of ARBs. Trials showed though discontinuation due to coughing in a minority of patients on ACEIs (2- - 3%). ARB prescribing restrictions in Austria as higher costs than ACEIs moderated utilisation. Other demand side measures in Spain (Catalonia) following generic ACEIs also moderated ARB utilisation.
Original languageEnglish
Article number482
Pages (from-to)S210-S210
JournalPharmacoepidemiology and Drug Safety
Volume20
Issue numberSuppl.1
DOIs
Publication statusPublished - 2011
Event27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management - Chicago, United States
Duration: 14 Aug 201117 Aug 2011

Keywords

  • receptor blockers
  • drug utilisation
  • Croatia

Cite this